Furthermore, recent years, cancer immunotherapy has shown clear benefits in the survival of cancer patients, especially immune checkpoint inhibitors (ICIs), such as programmed death- 1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte associated antigen 4 (CTLA4) inhibitors (8). This evidence concerns the gene CTLA4 and cancer.